Results 51 to 60 of about 6,910 (195)

Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.

PLoS ONE, 2020
BackgroundTreatment with vitamin K antagonists (VKA) requires a high proportion of time in the therapeutic range (TTR) and a low international normalised ratio (INR) variability to be maximally safe and effective.
Jasper H A van Miert, Nic J G M Veeger, Arina J Ten Cate-Hoek, Margriet Piersma-Wichers, Karina Meijer   +4 more
doaj   +1 more source

Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity

Obesity Reviews, Volume 26, Issue 12, December 2025.
ABSTRACT Introduction Although the physiologic alterations seen in obesity often affect the pharmacokinetics and pharmacodynamics of drugs, most clinical trials do not consider these aspects specifically for this population. To date, there is no list of potentially inappropriate medications for patients living with obesity. The aim of this study was to
Sarah Berdot, Germain Perrin, Emmanuel Disse, Armelle Arnoux, Eric Bertin, Anne‐Laure Borel, Marie‐Claude Brindisi, Arnaud De Luca, Edouard‐Jules Laforgue, Jean‐Daniel Lalau, Yann Matussiere, Emilie Montastier, Agnès Sallé, Bérénice Segrestin, Valentine Suteau, French Hospital Expert Panel, Sebastien Czernichow, Brigitte Sabatier   +17 more
wiley   +1 more source

Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms [version 2; peer review: 1 approved, 2 approved with reservations, 1 not approved]

F1000Research
Background Non-small-cell lung cancer (NSCLC) is a highly morbid disease. Chemotherapy for NSCLC lacks specificity and efficacy mainly because of drug resistance.
Bharath Harohalli Byregowda, K Sreedhara Ranganath Pai, Megh Pravin Vithalkar, Krishnaprasad Baby, Usha Y Nayak, Yogendra Nayak, Swastika Maity   +6 more
doaj   +1 more source

Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 803-812, October 2025.
The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar, Cathelijne H. van der Wouden, Lisanne E. N. Manson, Heshu Abdullah‐Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Erika Cecchin, Ka‐Chun Cheung, Vera H. M. Deneer, Siv Jonsson, Candace Joefield‐Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cristina L. Dávila‐Fajardo, Vita Dolžan, George P. Patrinos, Munir Pirmohamed, Gere Sunder‐Plassmann, Giuseppe Toffoli, Jesse J. Swen, Ubiquitous Pharmacogenomics Consortium   +37 more
wiley   +1 more source

Manejo del paciente anticoagulado con Acenocumarol en enfermería. Revisión Bibliográfica [PDF]

, 2019
Introducción. Las enfermedades cardiovasculares tienen una alta mortalidad a nivel mundial, además el envejecimiento de la población y el aumento de los factores de riesgo agravan esta situación.
Muñoz Biurrun, Laura
core  

A Scoping Review of Human Teratogens and Their Impact on the Developing Brain: A Contribution From the ConcePTION Project

Birth Defects Research, Volume 117, Issue 9, September 2025.
ABSTRACT Certain medications, when used during pregnancy, are known to impact human prenatal development. Historically, little attention has been given to the impact of in utero exposure on the developing brain, despite the significance of known teratogen‐induced neurodevelopmental difficulties.
M. Bluett‐Duncan, J. Adams, M. Berkovitch, M. Berlin, A. Cahoon, J. Clayton‐Smith, C. Jackson, S. Khanom, D. Mølgaard‐Nielsen, J. L. Richardson, V. Simms, M. Stellfeld, U. Winterfeld, L. M. Yates, R. L. Bromley   +14 more
wiley   +1 more source

Synthesis and structure of (R,S)-2-methyl-4-(4-nitrophenyl)-pyrano[3,2-c]chromen-5(4H)-one

Macedonian Journal of Chemistry and Chemical Engineering, 2012
In this paper, the synthesis and structure of a novel pyrano[3,2-c]coumarin, which was obtained unexpectedly in a reaction of phosphoryl chloride and acenocoumarol, are presented.
Rosica P. Nikolova, Boris Shivachev, Bozhana Mikhova, Bistra Stamboliyska, Kristina Mladenovska, Ana P. Panovska, Emil Popovski   +6 more
doaj   +1 more source

Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network

HemaSphere, Volume 9, Issue 8, August 2025.
Abstract Venous thromboembolism (VTE) is a frequent complication in patients with multiple myeloma (MM) that leads to increased morbidity, mortality, treatment interruptions, and reduced quality of life. Αn Expert Panel Consensus Guideline on behalf of the European Myeloma Network provides evidence‐based recommendations for VTE prevention and treatment
Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, Cihan Ay, Ramon Lecumberri, Alessandra Larocca, Gordon Cook, Monika Engelhardt, Sonja Zweegman, Michel Delforge, Anthony Maraveyas, Eleftheria Lefkou, Marina Marchetti, Niels W. C. J. Van de Donk, Francesca Gay, Heinz Ludwig, Hermann Einsele, Jesus F. San Miguel, Meletios A. Dimopoulos, Mario Boccadoro, Pieter Sonneveld, Anna Falanga, Evangelos Terpos   +22 more
wiley   +1 more source

Efficiency of treatment by acenocoumarol in patients with permanent form of atrial fibrillation, with using models of personalized medicine

RUDN Journal of Medicine, 2009
Acenocoumarol is the global standard of anticoagulant therapy, but often treatment with acenocoumarol accompanied by adverse drug reactions. Model of personalized medicine, actively developing now, can reduce the number of side effects during therapy of ...
I V Kukes, V N Shan
doaj  

Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion [PDF]

, 2017
The effects of the antiaggregant substance ticlopidine and of the anticoagulant acenocoumarol on patency rates of aorto-coronary bypass grafts were compared in a prospective randomized trial. Ticlopidine, 250 mg b.i.d.
GOEBEL, N., KRAYENBÜHL, H.-P, PFLUGER, N., ROTHLIN, M. E., SENNING, Å., SPEISER, K., STEINBRUNN, W., TURINA, M.   +7 more
core